IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the ...

A judge has rejected a request to throw out the conviction of a movie armorer in the fatal shooting of a cinematographer by ...

Some officials are calling for renewed restrictions on syringe service programs in Maine, saying they have contributed to the rise in used needles littering city streets. But harm reduction experts ...

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / (NASDAQ:MRNA) today announced that the first participant in the U.S. has ...